Suchergebnisse - "Salazar, Ramon"

PubPharm (9)

1

Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Hernando, J. | Roca-Herrera, M. | García-Álvarez, A. | +16

ErratumIn: Eur J Cancer. 2024 Apr 11;:114061. - PMID 38609739

2

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma : long term results

enthalten in: BMC cancer | 2020

von Salazar, R. | Capdevila, J. | Manzano, J. | +15

3

Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer

enthalten in: BMC cancer | 2015

von García, M. | Martinez-Villacampa, M. | Santos, C. | +13

4

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer : clinical and biological features

enthalten in: BMC cancer | 2015

von Salazar, R. | Capdevila, J. | Laquente, B. | +15

5

Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2014

von Salazar, R. | Calles, A. | Gil, M. | +9

6

Tenth anniversary of bevacizumab in colorectal cancer : has it fulfilled its promise?

enthalten in: Future oncology (London, England) | 2014

von Salazar, R. | Grasselli, J. | Santos, C. | +1

7

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour : a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

enthalten in: European journal of cancer (Oxford, England : 1990) | 2013

von Castellano, D. | Capdevila, J. | Sastre, J. | +7

8

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT) : a phase 3 randomised controlled trial

enthalten in: The Lancet. Oncology | 2012

von de Gramont, A. | Van Cutsem, E. | Schmoll, H. | +17

CommentIn: Lancet Oncol. 2012 Dec;13(12):1176-7. - PMID 23168364

9

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer : a double-blind, randomized phase III study (HORIZON III)

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012

von Schmoll, H. | Cunningham, D. | Sobrero, A. | +12

CommentIn: Nat Rev Clin Oncol. 2012 Nov;9(11):609. - PMID 23044776

1
[1]